Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trialJean-Pascal H. Machiels, Tim Henrik Brümmendorf, Robert I. Haddad et al.|RWTH Publications (RWTH Aachen)|2015Cited by 0
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemiaSebastian Stasik, Ralph Naumann, Hermann Einsele et al.|RWTH Publications (RWTH Aachen)|2021Cited by 0